Food and Drug Administration

Michael Burry's Scion Asset Management has acquired a stake in BioAtla, sending its shares up 14%. The cancer-drug developer's...

Jaguar Health's shares plummet 68% as cancer drug trial fails, but shows promise in breast and respiratory cancer subgroups....

In a major boost, MIRA Pharmaceuticals' shares soared after announcing promising preclinical results for its oral ketamine analog, Ketamir-2,...

Merrimack Pharmaceuticals is set to hold a special shareholder meeting to approve a plan for corporate dissolution, followed by...

In a major development, Disc Medicine has received orphan drug designation from regulators for its treatment of the rare...

In a major development, Better Therapeutics has signed a rebate agreement with a pharmacy benefit manager, allowing plan participants...

Vanda Pharmaceuticals has received a notification from the FDA regarding deficiencies in the supplemental new drug application for Hetlioz,...

Revance Therapeutics has received a permanent reimbursement code for its drug Daxxify, which is used to treat cervical dystonia...

Cabaletta Bio has received orphan drug designation from the FDA for its potential treatment for idiopathic inflammatory myopathies, a...

Altamira Therapeutics has seen a 13% increase in shares after filing a second provisional patent application for their cancer...